NCT03234556View on ClinicalTrials.gov

Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA

NAActive, not recruitingINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

September 25, 2017

Primary Completion Date

May 23, 2026

Study Completion Date

May 23, 2028

Conditions
Health Status UnknownElevated PSA
Interventions
PROCEDURE

Biopsy of Prostate

Undergo SR-Bx

OTHER

Laboratory Biomarker Analysis

Correlative studies

DIAGNOSTIC_TEST

Magnetic Resonance Imaging

Undergo MRI

DIAGNOSTIC_TEST

MRI Ultrasound Fusion Guided Biopsy

Undergo MRUS-Bx

Trial Locations (4)

10065

Memorial Sloan-Kettering Cancer Center, New York

21201

University of Maryland, Baltimore

48202

Henry Ford Hospital Vattikuti Urology Institute, Detroit

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER

NCT03234556 - Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA | Biotech Hunter | Biotech Hunter